Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2021 08:27 ET | Source: Acepodia USA

Acepodia Appoints Jimmy Lai as Chief Financial Officer

SAN MATEO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointment...
March 18, 2021 08:00 ET | Source: Acepodia USA

Acepodia to Present at the 6th Annual Innate Killer Summit

SAN MATEO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced that Sonny...
March 16, 2021 08:00 ET | Source: Acepodia USA

Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates

SAN MATEO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the closing of...
November 09, 2020 08:00 ET | Source: Acepodia USA

Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions ACE1702 maintains activity following cryopreservationoNK cell...
November 02, 2020 08:00 ET | Source: Acepodia USA

Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

SAN FRANCISCO and TAIPEI, Taiwan, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
October 22, 2020 11:02 ET | Source: Acepodia USA

Acepodia to Present at the 7th Annual China Healthcare Summit

SAN FRANCISCO and TAIPEI, Taiwan, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today...
September 01, 2020 08:00 ET | Source: Acepodia USA

Acepodia Strengthens Management Team with Appointments of Biotech Industry Veterans

SAN FRANCISCO and TAIPEI, Taiwan, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced...
August 18, 2020 07:30 ET | Source: Acepodia USA

Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients...
July 29, 2020 07:30 ET | Source: Acepodia USA

Acepodia to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

SAN FRANCISCO and TAIPEI, Taiwan, July 29, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) and...
July 14, 2020 07:30 ET | Source: Acepodia USA

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies

JW therapeutics to receive exclusive licenses to develop and commercialize ACE1702 and ACE1655 in Mainland China, Hong Kong, and Macau Acepodia to receive upfront and milestone payments in addition...